ArticleActa endocrinologica (Bucharest, Romania : 2005)
CURRENT TREATMENT APPROACHES AND GLYCEMIC CONTROL IN TURKISH PATIENTS WITH TYPE 2 DIABETES MELLITUS: A REAL-WORLD EVIDENCE FROM A TERTIARY HOSPITAL IN TURKEY.
Article in Acta endocrinologica (Bucharest, Romania : 2005). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study examined the glycemic control among adult patients with type 2 diabetes mellitus (T2DM) and their ongoing antidiabetic therapy focusing on potential differences in attaintment of glycemic control associated with the use of specific antidiabetic regimens (ADR). Design: This was a cross sectional study conducted between September 2019 and March 2020 at a tertiary hospital, department of Internal Medicine. Subjects and Methods: Patients with T2DM who had a diagnosis of T2DM for at least one year and used their prescribed ADR for at least 3 months were included in the study. Glycated hemoglobin (HbA1c) was used for evaluation of glycemic control. Results: A total of 500 patients aged 59.4 (±10.2) years, with 9.9 (±6.7) years of diabetes duration (54% women, BMI: 29.6±5.1kg/m Conclusions: Despite the introduction of novel drugs in the treatment of T2DM a majority of our patients fail to reach therapeutic goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.